FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer
by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura
Updated on: March 22,2024
17

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer
by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura
Updated on:March 22,2024
17
